Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Scott T. Tagawa, MD, MS, FASCO, FACP; Himisha Beltran, MD; and Neeta Pandit-Taskar, MD, MBA, discuss the latest evidence on PSMA PET and RLT, including combination strategies, selection, sequencing, toxicity monitoring, and operations, with careful attention to access and equity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the diagnostic and prognostic value of PSMA PET imaging and integrate imaging results into treatment planning for patients with advanced prostate cancer
• Develop evidence-based sequencing strategies incorporating PSMA radioligands alongside AR pathway inhibitors, chemotherapy, and novel investigational agents
• Identify real-world logistical, operational, and access-related barriers to PSMA-targeted imaging and therapy, and propose collaborative, multidisciplinary solutions to overcome them

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Chair:

Scott T. Tagawa, MD, MS, FASCO, FACP

Professor of Medicine & Urology
Weill Cornell Medicine
Meyer Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Abdera, AIkido Pharma, Amgen, Bayer AG, Biohaven, Blue Earth Diagnostics, Boston Scientific, Clarity Pharmaceuticals, Clovis Oncology, Convergent Therapeutics, Daiichi Sankyo, Eisai Co, EMD Serono, Endocyte, Genentech, General Electric, Genomic Health, Immunomedics, Janssen, Karyopharm Therapeutics, Lantheus, Medivation/Astellas Pharma, Merck, Myovant Sciences, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seagen, Telix Pharmaceuticals, Tolmar, TransThera; Grant/Research Funding: AbbVie, AIQ, Ambrx, Ambrx Biopharma, Amgen, Astellas Pharma, AstraZeneca, Bayer AG, Bristol Myers Squibb, Clarity, Clovis Oncology, Endocyte, Gilead Sciences, Immunomedics, Janssen, Janux, Karyopharm Therapeutics, Medivation, Merck, Novartis, POINT Biopharma, Sanofi , Seagen, Telix; Royalty or Patent Benefits: Convergent, Gilead; Ownership interests in privately held companies: Convergent

Faculty:

Himisha Beltran, MD

Associate Professor of Medicine
Director of Translational Research
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bayer, Daiichi Sankyo, Merck, Novartis; Grant/Research Funding: Circle Pharma, Daiichi Sankyo, Novartis

Neeta Pandit-Taskar, MD, MBA

Professor of Radiology
Chief, Division of Nuclear Medicine
Director, Theranostics (Molecular Imaging-and Radiopharmaceutical Therapy)
Vice Chair, Clinical and Translational Research
Department of Radiology
UPMC, University of Pittsburgh
Director, Oncologic Imaging
Hillman Cancer Center
Pittsburgh, PA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Actinium Pharmaceuticals, Blue Earth Diagnostics, Regeneron Pharmaceuticals, Telix Pharmaceuticals; Grant/Research Funding: Bristol Myers Squibb, Clarity Pharmaceuticals, Children’s Oncology Group (COG), Innervate Radiopharmaceuticals, Regeneron Pharmaceuticals

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the investigation of PSMA radioligand therapy in earlier lines of treatment, go to https://www.gotoper.com/courses/precision-in-practice-advancing-prostate-cancer-care-with-psma-directed-radioligand-therapy.

Release Date

January 26, 2026

Expiration Date

January 26, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.